ADC Therapeutics SA price to sales ratio ADCT
Market value divided by revenue over the last twelve months, since 2024.
- Today, Oct 23, 2026
- 2.3×
- Peer median
- 1.4×
ADC Therapeutics SA's price to sales ratio is 2.3× as of Oct 23, 2026.
The median for 10 large drugmakers of a similar size is 1.4×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 2.3× | 1.6× | 6.8× |
| 2025 | 5.8× | 1.7× | 7.1× |
| 2024 | 2.8× | 2.6× | 4.3× |
Against its peers
Companies in Drug Manufacturers - General nearest ADC Therapeutics SA's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| ADCTADC Therapeutics SA | 2.3× |
| NATRNatures Sunshine Products | 0.4× |
| LFVNLifevantage | 0.4× |
| ARVNArvinas | 1.5× |
| SPROSpero Therapeutics | 1.4× |
| PBYIPuma Biotechnology | 2.5× |
| IRWDIronwood Pharmaceuticals | 1.5× |
| ZVRAZevra Therapeutics | 4.3× |
| CRMDCorMedix | 1.3× |
| ATNMActinium Pharmaceuticals | n/m |
| COLLCollegium Pharmaceutical | 0.9× |
| Peer median | 1.4× |
Where ADC Therapeutics SA ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on ADC Therapeutics SA
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.